I wasn't seriously suggesting that TRIL try a PD1/CTLA4 combo anytime soon, just commenting that when you give something like CTLA4 that revs up the immune system greatly then if your combo drug is indeed immunogenic you might end up in trouble.
There are so many possible IO combos out there now that I think only the big pharma are going to be able to figure out the best ones to try.
Sally had a nice write up about NKTR-214's SITC presentation. I don't know if it was supposed to be behind the paywall or not but I saw a tweet to it and it seems freely available. Its a very nice discussion with interview and I can see why her sub is worthwhile for those with the interest/resources in Oncology drugs.
News 
Market Data 
Discover 
